Indian HRT market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
For many years, women have been prescribed estrogen with or without Progestin Hormone Replacement Therapy (HRT) to relieve some of the symptoms of menopause. India has a large population, which has already crossed the 1 billion mark with 71 million people over 60 years of age and the number of menopausal women about 43 million. It’s estimated the population in India will be 1.4 billion, people over 60 years 173 million, and the menopausal population 103 million. Average age of menopause is 47.5 years in Indian women with an average life expectancy of 71 years. HRT has gained ground in India, with an increasing number of women, mostly from metropolitan regions, opting for HRT to deal with menopausal symptoms, like osteoporosis, osteopenia, hot flushes, mood swings, sexual dysfunction, etc on medical advice. Over 50 million Indian women are of menopausal age, but alternative treatments for their symptoms, ranging from antidepressants to bioidentical hormones, are limited in efficacy or scope. The rise in prevalence of menopausal disorder and increase in awareness about post-menopausal issues among women. In addition, new launches of hormone replacement therapy are expected to notably contribute toward the hormone replacement therapy market growth.
The significant factors that contribute toward the growth of the hormone replacement therapy market include a rise in the prevalence of menopausal disorder and an increase in awareness about post-menopausal issues among women. New launches of hormone replacement therapy are expected to contribute to the hormone replacement therapy market growth notably. However, adverse effects of hormone replacement therapy and the high cost of treatment are anticipated to hamper the market growth during the forecast period. On the contrary, the introduction of bioidentical hormone replacement therapy and leveraging telemedicine for hormone replacement therapy are expected to provide the remunerative opportunity to expand the hormone replacement therapy market.